title: [Azithromycin as a novel treatment for bronchiolitis obliterans syndrome].
abstract: Bronchiolitis obliterans syndrome (BOS) is one of the main causes of mortality after lung and bone marrow transplantation. Up to 75% of lung transplantation patients develop BOS within 5 years, whereas after bone marrow transplantation 14% of the patients develop the disease with 65% mortality within 3 years. Patients demonstrate gradual decrease in pulmonary functions with no significant anatomic/imagine findings. Therapeutic trials with high dose systemic corticosteroids, immune suppression and immunomodulation did not show any significant success. However, macrolides and especially azithromycin have recently been reported as highly efficient for BOS. This review summarizes information on the disease focusing on the clinical experience with azithromycin as a treatment for BOS.
authors: Pulmonary Institute, Rabin Medical Center, Beilinson Campus, Petah Tikva. peledbn@zahav.net.il
authors: Nir
authors: N
authors: Peled
authors: David
authors: D
authors: Shitrit
authors: Daniele
authors: D
authors: Bendayan
authors: Mordechai R
authors: MR
authors: Kramer
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D017963:Azithromycin / Q000627:therapeutic use*; D001989:Bronchiolitis Obliterans / Q000188:drug therapy*; D006801:Humans; D014374:Tuberculin Test; D014376:Tuberculosis / Q000628:therapy
chemical_list: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D017963:Azithromycin